Stony Brook Heart Institute cardiologists are continually exploring new approaches to care for heart and valve disease patients, especially those too ill for open-heart surgery or those who might have limited treatment options. In the latest chapter in Stony Brook’s state-of-the-art, minimally invasive frontline treatments, the Heart Institute has been selected to participate in the first-phase clinical trial for a new type of minimally invasive intravascular “patch” in advance of submission for approval by the U.S. Food and Drug Administration (FDA). Stony Brook is one of only five elite sites nationwide and the only facility on Long Island to be chosen to take part.
Approved for use in Europe in 2018, the first generation of the device is a sutureless, fully-absorbable intravascular ‘patch’ that seals an artery from the inside after heart valve repair or replacement. The next generation of the device is designed to address more complex patient anatomies.
For the first time in the U.S., this new arterial-closing technique using PerQseal®+ was performed on March 8, 2022 by Henry J. Tannous, MD, and Robert T. Pyo, MD, at Stony Brook University Hospital during a transcatheter aortic valve procedure (TAVR).
“Closing the artery has been a universal concern since less invasive techniques have been used for valve implantation,” said Robert T. Pyo, MD, Director, Interventional Cardiology; Medical Director, Structural Heart Program and Associate Professor, Renaissance School of Medicine at Stony Brook University. “To date, there has been no universally accepted way to close the implantation hole, whether applying pressure for up to two hours or utilizing a suture.”
“Safe, quick and effective blood vessel closure is key to a successful outcome in patients undergoing an endovascular heart valve procedure,” says Henry J. Tannous, MD, Co-Director, Stony Brook Heart Institute; Chief, Cardiothoracic Surgery; Surgical Director, Structural Heart Program; and General T.F. Cheng Chair, Cardiothoracic Surgery, Renaissance School of Medicine at Stony Brook University. “At the Heart Institute, we are continually focused on exploring new options to improve outcomes and quality of life.”
Minimally invasive, lifesaving techniques for at-risk patients, which include utilizing the Impella® ventricular support system and transcatheter aortic valve replacement (TAVR), have soared in use over the past decade. These approaches, using compression or sutures to close the large-size percutaneous (through the skin) implantation holes, have not kept pace with the evolving technology. The intent of this type of minimally invasive intravascular “patch” is to fill that gap.
Stony Brook University Heart Institute is located within Stony Brook University Hospital as part of Long Island’s premier university-based medical center. The Heart Institute offers a comprehensive, multidisciplinary program for the prevention, diagnosis and treatment of cardiovascular disease, and provides state-of-the-art interventional and surgical capabilities in 24-hour cardiac catheterization labs and surgical suites. Its physician-scientists are also actively enhancing knowledge of the heart and blood vessels through basic biomedical studies and clinical research.